Evidence for nociceptin opioid peptide receptor (NOP) expression and nociceptin/orphanin FQ (N/OFQ) release from live B and T cells

被引：0
|
作者：
Bird, M. F. [1 ]
Willets, J. M. [2 ]
Thompson, J. P. [1 ]
Guerrini, R. [3 ,4 ,5 ,6 ]
Calo, G. [6 ,7 ]
Lambert, D. G. [1 ]
机构：
[1] Univ Leicester, Dept Cardiovasc Sci, Div Anaesthesia Crit Care & Pain Management, Leicester Royal Infirm, Leicester, Leics, England
[2] Univ Leicester, Dept Mol & Cellular Biol, Henry Wellcome Bldg, Leicester, Leics, England
[3] Univ Ferrara, Dept Chem & Pharmaceut Sci, Ferrara, Italy
[4] Univ Ferrara, Lab Tecnol Terapie Avanzate, Ferrara, Italy
[5] Univ Ferrara, Pharmacol Sect, Ferrara, Italy
[6] Univ Ferrara, Natl Inst Neurosci, Ferrara, Italy
[7] Univ Ferrara, Dept Med Sci, Pharmacol Sect, Ferrara, Italy
来源：
BRITISH JOURNAL OF ANAESTHESIA | 2018年 / 121卷 / 02期
基金：
英国生物技术与生命科学研究理事会;
关键词：
D O I：
10.1016/j.bja.2018.05.024
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
引用
收藏
页码：E22 / E23
页数：3
相关论文
共 50 条
  • [31] Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems
    Norton, CS
    Neal, CR
    Kumar, S
    Akil, H
    Watson, SJ
    JOURNAL OF COMPARATIVE NEUROLOGY, 2002, 444 (04) : 358 - 368
  • [32] Heterodimerization of mu opioid receptor and nociceptin/orphanin FQ peptide receptor alters g protein coupling
    Gunduz, O.
    Baldini, E.
    Borsodi, A.
    Benyhe, S.
    Corbani, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S280 - S281
  • [33] Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal
    Aujla, Harinder
    Cannarsa, Rosalia
    Romualdi, Patrizia
    Ciccocioppo, Roberto
    Martin-Fardon, Remi
    Weiss, Friedbert
    ADDICTION BIOLOGY, 2013, 18 (03) : 467 - 479
  • [34] Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat
    Tzschentke, Thomas M.
    Rutten, Kris
    NEUROPHARMACOLOGY, 2018, 129 : 100 - 108
  • [35] Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists
    Sugimoto, Yuichi
    Shimizu, Atsushi
    Kato, Tetsuya
    Satoh, Atsushi
    Ozaki, Satoshi
    Ohta, Hisashi
    Okamoto, Osamu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (13) : 3569 - 3573
  • [36] Effects of Mu Opioid Peptide (MOP)/Nociceptin-Orphanin FQ Peptide (NOP) Receptor Agonists on Ethanol Drinking in Male and Female Cynomolgus Monkeys
    Prete, Joshua
    Czoty, Paul W.
    Epperly, Phillip M.
    Husbands, Steve M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (03):
  • [37] Effects of BU08028, a Mixed Mu Opioid Receptor and Nociceptin/Orphanin FQ Peptide (NOP) Receptor Agonist, on Alcohol Drinking in Rhesus Monkeys
    Czoty, Paul
    Epperly, Phillip
    Davenport, April
    Ko, Mei-Chuan
    Husbands, Stephen
    Flynn, Shawn
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S630 - S630
  • [38] In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells
    Bird, Mark F.
    Gallacher-Horley, Barbara
    McDonald, John
    McVey, David G.
    Al-Janabi, Fatin
    Guerrini, Remo
    Calo, Girolamo
    Ye, Shu
    Thompson, Jonathan P.
    Lambert, David G.
    PLOS ONE, 2022, 17 (09):
  • [39] Centrally administered nociceptin/orphanin FQ (N/OFQ) evokes bradycardia, hypotension, and diuresis in mice via activation of central N/OFQ peptide receptors
    Burmeister, Melissa A.
    Kapusta, Daniel R.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (01): : 324 - 331
  • [40] Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers
    Dahan, Albert
    Boom, Merel
    Sarton, Elise
    Hay, Justin
    Groeneveld, Geert Jan
    Neukirchen, Meike
    Bothmer, John
    Aarts, Leon
    Olofsen, Erik
    ANESTHESIOLOGY, 2017, 126 (04) : 697 - 707
12345